PTC Therapeutics Shares 24-Month Votoplam Data Showing Dose-Linked Huntington's Slowing Signals [Yahoo! Finance]
PTC Therapeutics, Inc. (PTCT)
Last ptc therapeutics, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.ptcbio.com
Company Research
Source: Yahoo! Finance
a matched natural-history cohort — about slowing at 10 mg and at 5 mg on the cUHDRS — though differences were not statistically significant (10 mg trended with p Safety and biomarkers remained favorable after 24 months with no treatment-related NfL spikes (median NfL below baseline for both doses) and no new adverse-event signals, while Stage 3 participants showed emerging functional benefit on the TFC subscale. PTC and Novartis have initiated the Phase 3 INVEST-HD trial (˜770 patients, 3:2 randomization to 10 mg vs placebo, up to 36 months); Phase 3 start triggers a $50M milestone and could support accelerated-approval discussions pending interim analyses. Interested in PTC Therapeutics, Inc.? Here are five stocks we like better. PTC Therapeutics (NASDAQ:PTCT) reported top-line results from a 24-month interim analysis of the PIVOT-HD long-term extension (LTE) study evaluating Votoplam in Huntington's disease, highlighting what the company described as continued favorable safe
Show less
Read more
Impact Snapshot
Event Time:
PTCT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTCT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTCT alerts
High impacting PTC Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
PTCT
News
- PTC Therapeutics Reports Positive Topline Results from Month 24 Interim Analysis of PIVOT-HD Extension Study of VotoplamPR Newswire
- PTC Therapeutics to Report Results from PIVOT-HD Long Term Extension StudyPR Newswire
- PTC Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026PR Newswire
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- PTC Therapeutics (PTCT) was upgraded by Raymond James Financial, Inc. to "moderate buy".MarketBeat
PTCT
Earnings
- 2/19/26 - Miss
PTCT
Sec Filings
- 4/29/26 - Form SCHEDULE
- 4/28/26 - Form 8-K
- 4/23/26 - Form 4
- PTCT's page on the SEC website